Montserrat Domènech

Althaia — Spain

Medicine · Health Sciences

20h-index1.4kcitations136works1.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(32), Bladder and Urothelial Cancer Treatments(26), Urinary and Genital Oncology Studies(16), BRCA gene mutations in cancer(15), Radiopharmaceutical Chemistry and Applications(13)

Publications135 total

Unveiling Oligometastatic Urothelial Carcinoma (OUC): A multicenter retrospective study on clinical patterns and outcomes
European Urology Open Science·2025Open Access
Implementation of the precision oncology program in catalonia’s public health system: results, lessons learned, and future prospects
Clinical & Translational Oncology·2025· 1 citedOpen Access
Corrigendum to “Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients” [Eur. Urol. Oncol. 7 (2024) 954–964]
European Urology Oncology·2025
Biomarker-Based Nomogram to Predict Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer
Biomedicines·2025· 2 citedOpen Access
Evaluating the Quality of Real-World Data on Adherence to Oral Endocrine Therapy in Breast Cancer Patients: How Real Is Real-World Data?
Cancers·2025· 2 citedOpen Access
20224. MARCADORES DE NEUROIMAGEN Y FUNCIÓN COGNITIVA EN PACIENTES CON HEMATOMA LOBAR Y/O CORTICAL ASOCIADO A ANGIOPATÍA AMILOIDE CEREBRAL
Neurology Perspectives·2024Open Access
P272 A nomogram for predicting survival in Muscle-Invasive Bladder Cancer (MIBC) patients (p) treated with Neoadjuvant Chemotherapy (NAC)
European Urology Open Science·2024Open Access
Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study
Clinical & Translational Oncology·2024
Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients
European Urology Oncology·2024· 10 citedOpen Access
Implementation of a protocol for the management of elderly patients with elevated PSA
Journal of Geriatric Oncology·2023
Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features
Frontiers in Oncology·2023· 4 citedOpen Access
Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment
Clinical & Translational Oncology·2023· 3 cited
Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel
Cancers·2022· 10 citedOpen Access
Nomogram based on baseline clinicopathological characteristics for predicting bladder cancer-specific survival to neoadjuvant chemotherapy in muscle-invasive bladder cancer
World Journal of Urology·2022· 3 cited
SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021)
Clinical & Translational Oncology·2022· 17 citedOpen Access
Phase I-II study to evaluate safety and efficacy of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial): Preliminary data of phase I study.
Journal of Clinical Oncology·2022· 3 cited
Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in Muscle-Invasive Bladder Cancer (MIBC) patients
European Urology·2021
Association of androgen receptor signature and <i>RB1</i>, <i>PTEN</i>, <i>TP53</i> gene expression with clinical outcome in metastatic hormone-sensitive prostate cancer treated with docetaxel and androgen deprivation therapy.
Journal of Clinical Oncology·2021
Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
Frontiers in Oncology·2020· 16 citedOpen Access
LBA27 Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy
Annals of Oncology·2020· 10 cited
page 1 of 7Next →

Frequent Co-authors

Montserrat Baiget(20), Begoña Mellado(12), Joan Carles(9), Orland Dı́ez(8), Pablo Maroto(7), Aranzazu González del Alba(7), Enrique Gallardo(7), Eduardo F. Tizzano(7), Albert Font(7), Carmen Alonso(6), Albert Font(6), Javier Puente(6), Cristina Suárez(6), Alejo Rodríguez‐Vida(6), Xavier García del Muro(5), Berta Campos(5), Núria Laínez(5), Daniel Castellano(5), Joaquim Bellmunt(5), Manel Baena(4)